Kailun Fei

1.3k total citations · 1 hit paper
23 papers, 706 citations indexed

About

Kailun Fei is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Kailun Fei has authored 23 papers receiving a total of 706 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Kailun Fei's work include Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Research Studies (4 papers). Kailun Fei is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), Cancer Immunotherapy and Biomarkers (11 papers) and Lung Cancer Research Studies (4 papers). Kailun Fei collaborates with scholars based in China, United States and Sweden. Kailun Fei's co-authors include Jie Wang, Zhijie Wang, Hua Bai, Jianchun Duan, Xin Wang, Rui Wan, Jiachen Xu, Zhuoran Yao, Jianchun Duan and Yanhua Tian and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Science Advances.

In The Last Decade

Kailun Fei

23 papers receiving 699 citations

Hit Papers

Treatment-related adverse events of PD-1 and PD-L1 inhibi... 2021 2026 2022 2024 2021 50 100 150
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis
    2021 160 citations Xiaoxiang Zhou, Zhuoran Yao et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kailun Fei China 14 481 265 187 184 101 23 706
Xinxin Zhu China 13 387 0.8× 144 0.5× 242 1.3× 157 0.9× 111 1.1× 19 650
Muhammad Zubair Afzal United States 11 383 0.8× 175 0.7× 143 0.8× 166 0.9× 98 1.0× 31 543
Leslie Rozeboom United States 13 575 1.2× 207 0.8× 313 1.7× 191 1.0× 102 1.0× 16 767
Matilde Saggese United Kingdom 14 389 0.8× 377 1.4× 168 0.9× 260 1.4× 137 1.4× 25 804
Keren Jia China 11 299 0.6× 193 0.7× 134 0.7× 124 0.7× 99 1.0× 20 523
Emilio Francesco Giunta Italy 15 386 0.8× 174 0.7× 96 0.5× 210 1.1× 82 0.8× 61 646
Dan Sha China 7 372 0.8× 210 0.8× 114 0.6× 204 1.1× 211 2.1× 16 644
Annegé Vledder Netherlands 4 404 0.8× 126 0.5× 307 1.6× 139 0.8× 103 1.0× 9 626
Lingdi Zhao China 15 319 0.7× 140 0.5× 167 0.9× 125 0.7× 62 0.6× 55 518

Countries citing papers authored by Kailun Fei

Since Specialization
Citations

This map shows the geographic impact of Kailun Fei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kailun Fei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kailun Fei more than expected).

Fields of papers citing papers by Kailun Fei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kailun Fei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kailun Fei. The network helps show where Kailun Fei may publish in the future.

Co-authorship network of co-authors of Kailun Fei

This figure shows the co-authorship network connecting the top 25 collaborators of Kailun Fei. A scholar is included among the top collaborators of Kailun Fei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kailun Fei. Kailun Fei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liu, Lihui, Sini Li, Yan Qu, et al.. (2023). Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity. Cell Reports Medicine. 4(10). 101206–101206. 30 indexed citations
3.
Zhang, Guochao, Renda Li, Zhenlong Yuan, et al.. (2023). Development and validation of a nomogram based on preoperative variables for predicting recurrence‐free survival in stage IA lung adenocarcinoma. Thoracic Cancer. 14(31). 3108–3118. 1 indexed citations
4.
5.
Zhao, Jie, Hua Bai, Fan Bai, et al.. (2023). Multi-omics indicators of long-term survival benefits after immune checkpoint inhibitor therapy. Cell Reports Methods. 3(10). 100596–100596. 6 indexed citations
6.
Fei, Kailun, Lei Guo, Yulan Wang, et al.. (2023). CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations. Journal of Thoracic Oncology. 19(4). 613–625. 7 indexed citations
7.
Zhong, Jia, Hua Bai, Zhijie Wang, et al.. (2023). Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions. Frontiers of Medicine. 17(1). 18–42. 12 indexed citations
8.
Xu, Wenjie, Kailun Fei, Yalong Wang, et al.. (2022). Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trials. Frontiers in Oncology. 12. 970557–970557. 15 indexed citations
9.
Zhang, Pei, Yang Du, Hua Bai, et al.. (2022). Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors. BMC Medicine. 20(1). 435–435. 26 indexed citations
10.
Liu, Lihui, Sini Li, Yan Qu, et al.. (2022). Tumour ERO1A instigates T cell dysfunction by transmission of endoplasmic reticulum stress.. Journal of Clinical Oncology. 40(16_suppl). e14533–e14533. 1 indexed citations
11.
Sun, Sijin, Kailun Fei, Guochao Zhang, et al.. (2021). Construction and Comprehensive Analyses of a METTL5-Associated Prognostic Signature With Immune Implication in Lung Adenocarcinomas. Frontiers in Genetics. 11. 617174–617174. 17 indexed citations
12.
Yu, Ruofei, Hua Bai, Jiefei Han, et al.. (2021). TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib. Translational Oncology. 14(9). 101163–101163. 17 indexed citations
13.
Zhou, Xiaoxiang, Zhuoran Yao, Hua Bai, et al.. (2021). Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. The Lancet Oncology. 22(9). 1265–1274. 160 indexed citations breakdown →
14.
Zhang, Fan, Hua Bai, Ranran Gao, et al.. (2020). Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Cancer Immunology Immunotherapy. 69(12). 2599–2611. 27 indexed citations
15.
Tian, Yanhua, Jiachen Xu, Qian Chu, et al.. (2020). A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients. BMC Medicine. 18(1). 232–232. 22 indexed citations
16.
Bai, Hua, Jianchun Duan, Chengcheng Li, et al.. (2020). EPHA mutation as a predictor of immunotherapeutic efficacy in lung adenocarcinoma. Journal for ImmunoTherapy of Cancer. 8(2). e001315–e001315. 27 indexed citations
17.
Wang, Zhijie, Jianming Ying, Jiachen Xu, et al.. (2020). Safety, Antitumor Activity, and Pharmacokinetics of Toripalimab, a Programmed Cell Death 1 Inhibitor, in Patients With Advanced Non–Small Cell Lung Cancer. JAMA Network Open. 3(10). e2013770–e2013770. 32 indexed citations
18.
He, Xiran, Yang Du, Zhijie Wang, et al.. (2020). Upfront dose-reduced chemotherapy synergizes with immunotherapy to optimize chemoimmunotherapy in squamous cell lung carcinoma. Journal for ImmunoTherapy of Cancer. 8(2). e000807–e000807. 40 indexed citations
19.
Han, Jiefei, Jianchun Duan, Hua Bai, et al.. (2019). TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(1). 146–154. 177 indexed citations
20.
Jü, Rui, Kailun Fei, Chen Chen, et al.. (2018). Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy. Journal of Pharmacology and Experimental Therapeutics. 367(1). 20–27. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xinxin Zhu Breakdown of academic impact, for papers by Muhammad Zubair Afzal Breakdown of academic impact, for papers by Leslie Rozeboom Breakdown of academic impact, for papers by Matilde Saggese Breakdown of academic impact, for papers by Keren Jia Breakdown of academic impact, for papers by Emilio Francesco Giunta Breakdown of academic impact, for papers by Dan Sha Breakdown of academic impact, for papers by Annegé Vledder Breakdown of academic impact, for papers by Lingdi Zhao
Rankless by CCL
2026